NCT06252649 2026-02-27
CodeBreaK 301
Amgen
Phase 3 Recruiting
Clinical Trials
8 trialsNCT05198934 2026-02-06
CodeBreak300
Amgen
Phase 3 Active not recruiting
NCT02394795 2023-11-01
PARADIGM
Takeda
Phase 3 Completed
NCT00113763 2022-11-07
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00364013 2022-11-07
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Amgen
Phase 3 Completed
NCT01001377 2022-09-21
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00115765 2018-10-17
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Amgen
Phase 3 Completed
NCT01412957 2017-03-15
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
Amgen
Phase 3 Completed